Summary
220.15 2.98(1.37%)05/17/2024
Madrigal Pharmaceuticals Inc (MDGL)
Madrigal Pharmaceuticals Inc (MDGL)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -7.71 | 6.44 | -12.51 | 15.45 | 42.97 | -29.59 | 110.29 | -31.65 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 217.47 | |
| Open | 222.00 | |
| High | 230.49 | |
| Low | 214.96 | |
| Volume | 727,983 | |
| Change | -18.17 | |
| Change % | -7.71 | |
| Avg Volume (20 Days) | 435,093 | |
| Volume/Avg Volume (20 Days) Ratio | 1.67 | |
| 52 Week Range | 119.76 - 313.11 | |
| Price vs 52 Week High | -30.55% | |
| Price vs 52 Week Low | 81.58% | |
| Range | -2.04 | |
| Gap Up/Down | -14.65 | |
Fundamentals | ||
| Market Capitalization (Mln) | 4,523 | |
| EBIDTA | -66,505,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 172.36 | |
| Book Value | 13.9310 | |
| Earnings Per Share | -14.6540 | |
| EPS Estimate Current Quarter | -3.9000 | |
| EPS Estimate Next Quarter | -3.9100 | |
| EPS Estimate Current Year | -14.7800 | |
| EPS Estimate Next Year | -14.2600 | |
| Diluted EPS (TTM) | -14.6540 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | -0.4606 | |
| Return on equity (TTM) | -0.9014 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 5.2657 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 17,097,100 | |
| Shares Float | 8,569,745 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 18.18 | |
| Institutions (%) | 76.84 | |
05/07 11:24 EST - seekingalpha.com
Madrigal Pharmaceuticals (MDGL) Q1 2024 Earnings Call Transcript
Madrigal Pharmaceuticals (NASDAQ:MDGL ) Q1 2024 Results Conference Call May 7, 2024 8:00 AM ET Company Participants Tina Ventura - Chief IRO Bill Sibold - CEO Mardi Dier - CFO Conference Call Participants Yasmeen Rahimi - Piper Sandler Eli Merle - UBS Liisa Bayko - Evercore Jay Olson - Oppenheimer Ritu Baral - TD Cowen Thomas Smith - Leerink Partners Akash Tewari - Jefferies Jon Wolleben - Citizens Andrea Tan - Goldman Sachs Operator Good day, and thank you for standing by. Welcome to Madrigal Pharmaceuticals First Quarter 2024 Earnings Conference Call.
Madrigal Pharmaceuticals (MDGL) Q1 2024 Earnings Call Transcript
Madrigal Pharmaceuticals (NASDAQ:MDGL ) Q1 2024 Results Conference Call May 7, 2024 8:00 AM ET Company Participants Tina Ventura - Chief IRO Bill Sibold - CEO Mardi Dier - CFO Conference Call Participants Yasmeen Rahimi - Piper Sandler Eli Merle - UBS Liisa Bayko - Evercore Jay Olson - Oppenheimer Ritu Baral - TD Cowen Thomas Smith - Leerink Partners Akash Tewari - Jefferies Jon Wolleben - Citizens Andrea Tan - Goldman Sachs Operator Good day, and thank you for standing by. Welcome to Madrigal Pharmaceuticals First Quarter 2024 Earnings Conference Call.
05/07 07:00 EST - globenewswire.com
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
CONSHOHOCKEN, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today reports first-quarter 2024 financial results and provides corporate updates.
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
CONSHOHOCKEN, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today reports first-quarter 2024 financial results and provides corporate updates.
04/30 16:30 EST - seekingalpha.com
Madrigal: Rezdiffra Launch Gets Underway, The Only Competition Is Off-Label
MDGL has launched Rezdiffra, the first drug approved for nonalcoholic steatohepatitis (NASH). Rezdiffra faces competition from potential off-label use of GLP-1RA drugs like semaglutide and tirzepatide, but there is potential for combination therapy too. Shortages of semaglutide and tirzepatide could help Rezdiffra's initial launch.
Madrigal: Rezdiffra Launch Gets Underway, The Only Competition Is Off-Label
MDGL has launched Rezdiffra, the first drug approved for nonalcoholic steatohepatitis (NASH). Rezdiffra faces competition from potential off-label use of GLP-1RA drugs like semaglutide and tirzepatide, but there is potential for combination therapy too. Shortages of semaglutide and tirzepatide could help Rezdiffra's initial launch.
04/24 16:00 EST - globenewswire.com
Madrigal Statement on the Passing of Dr. Stephen Harrison
CONSHOHOCKEN, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- The Madrigal team is shocked and saddened to learn of the passing of Dr. Stephen Harrison.
Madrigal Statement on the Passing of Dr. Stephen Harrison
CONSHOHOCKEN, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- The Madrigal team is shocked and saddened to learn of the passing of Dr. Stephen Harrison.
04/16 16:05 EST - globenewswire.com
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., April 16, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to 7 new employees, in each case with a grant date of April 15, 2024, as equity inducement awards under the terms of the company's 2023 Inducement Plan. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., April 16, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to 7 new employees, in each case with a grant date of April 15, 2024, as equity inducement awards under the terms of the company's 2023 Inducement Plan. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
04/15 07:52 EST - investorplace.com
7 Stocks Analysts Are Loving Right Now (And You Should Too): April 2024
Many investors have one or more preferred fundamental or technical indicator. These help to cut through the noise surrounding a stock.
7 Stocks Analysts Are Loving Right Now (And You Should Too): April 2024
Many investors have one or more preferred fundamental or technical indicator. These help to cut through the noise surrounding a stock.
04/10 10:15 EST - fool.com
2 Under-the-Radar Growth Stocks to Consider
Madrigal Pharmaceuticals recently earned a groundbreaking therapy approval. Axsome Therapeutics is getting closer to transforming its lineup of medicines.
2 Under-the-Radar Growth Stocks to Consider
Madrigal Pharmaceuticals recently earned a groundbreaking therapy approval. Axsome Therapeutics is getting closer to transforming its lineup of medicines.
04/05 07:15 EST - fool.com
Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics
Madrigal Pharmaceuticals just commercialized its first medicine. Viking Therapeutics has a mid-stage candidate with great potential.
Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics
Madrigal Pharmaceuticals just commercialized its first medicine. Viking Therapeutics has a mid-stage candidate with great potential.
04/03 08:45 EST - fool.com
1 No-Brainer Growth Stock to Buy Now
Madrigal Pharmaceuticals scored a historical regulatory approval last month. Even so, the market has been taking a cautious approach to Madrigal's shares.
1 No-Brainer Growth Stock to Buy Now
Madrigal Pharmaceuticals scored a historical regulatory approval last month. Even so, the market has been taking a cautious approach to Madrigal's shares.
04/01 21:09 EST - investorplace.com
The 3 Best Biotech Stocks to Buy in April 2024
Right now, biotech is one of the hottest sectors on the market, creating big opportunities for some of the best biotech stocks to buy in April. All of this is thanks to new innovation, millions of retiring baby boomers, demand for better care, pharmaceutical companies nearing patent expirations, a resurgence of mergers and acquisitions, and even new treatments that'll help you shed weight.
The 3 Best Biotech Stocks to Buy in April 2024
Right now, biotech is one of the hottest sectors on the market, creating big opportunities for some of the best biotech stocks to buy in April. All of this is thanks to new innovation, millions of retiring baby boomers, demand for better care, pharmaceutical companies nearing patent expirations, a resurgence of mergers and acquisitions, and even new treatments that'll help you shed weight.
03/29 09:00 EST - fool.com
Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals
Viking's drug candidate has shown promise in clinical studies as a potential weight loss medicine. Madrigal just launched the first (and so far only) medicine approved by the U.S. for NASH.
Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals
Viking's drug candidate has shown promise in clinical studies as a potential weight loss medicine. Madrigal just launched the first (and so far only) medicine approved by the U.S. for NASH.
03/29 04:43 EST - fool.com
Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval?
The Food and Drug Administration recently granted accelerated approval for Rezdiffra, a potential blockbuster for Madrigal Pharmaceuticals. At its peak, the drug could bring in more than $5 billion in revenue per year.
Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval?
The Food and Drug Administration recently granted accelerated approval for Rezdiffra, a potential blockbuster for Madrigal Pharmaceuticals. At its peak, the drug could bring in more than $5 billion in revenue per year.
03/28 14:56 EST - zacks.com
2 Top Biotech Buyout Candidates
After a strong resurgence in the back half of 2023 and continued momentum into the first quarter of 2024, biotech stocks are back in vogue. “Hawkish” Federal Reserve Policy, a brutal bear market in 2022, and investor preference for big tech stocks have meant underperformance for biotech stocks.
2 Top Biotech Buyout Candidates
After a strong resurgence in the back half of 2023 and continued momentum into the first quarter of 2024, biotech stocks are back in vogue. “Hawkish” Federal Reserve Policy, a brutal bear market in 2022, and investor preference for big tech stocks have meant underperformance for biotech stocks.
03/22 06:15 EST - fool.com
This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy?
Madrigal earned the first approval for a medicine in an area with a high unmet need. The commercial opportunity for this therapy, which treats a liver disease, looks exciting.
This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy?
Madrigal earned the first approval for a medicine in an area with a high unmet need. The commercial opportunity for this therapy, which treats a liver disease, looks exciting.
03/19 05:50 EST - fool.com
Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?
Last week's FDA approval of Rezdiffra in treating NASH is a huge milestone for Madrigal. Lilly and Novo Nordisk look much more impressive than Madrigal in most ways.
Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?
Last week's FDA approval of Rezdiffra in treating NASH is a huge milestone for Madrigal. Lilly and Novo Nordisk look much more impressive than Madrigal in most ways.
03/18 23:58 EST - globenewswire.com
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
CONSHOHOCKEN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced the pricing of its underwritten public offering of 750,000 shares of its common stock at a public offering price of $260.0000 per share, and, to certain investors, pre-funded warrants to purchase 1,557,692 shares of common stock at a price of $259.9999 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The size of the offering was increased by $100 million subsequent to the initial announcement of the offering. The gross proceeds to Madrigal from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $600 million. Madrigal has granted the underwriters of the offering a 30-day option to purchase up to an additional 346,153 shares of common stock from the company at the public offering price, less underwriting discounts and commissions.
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
CONSHOHOCKEN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced the pricing of its underwritten public offering of 750,000 shares of its common stock at a public offering price of $260.0000 per share, and, to certain investors, pre-funded warrants to purchase 1,557,692 shares of common stock at a price of $259.9999 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The size of the offering was increased by $100 million subsequent to the initial announcement of the offering. The gross proceeds to Madrigal from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $600 million. Madrigal has granted the underwriters of the offering a 30-day option to purchase up to an additional 346,153 shares of common stock from the company at the public offering price, less underwriting discounts and commissions.
03/18 20:01 EST - investorplace.com
7 Biotech Stocks Ready to Ride the Sector's Resurgence
Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation.
7 Biotech Stocks Ready to Ride the Sector's Resurgence
Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation.
03/18 16:04 EST - globenewswire.com
Madrigal Pharmaceuticals Announces Proposed Public Offering
CONSHOHOCKEN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that it has commenced an underwritten public offering of $500 million in shares of its common stock and pre-funded warrants to purchase common stock. The purchase price of each pre-funded warrant will equal the price per share at which shares of common stock are being sold to the public in this offering, minus $0.0001, which will be the per share exercise price of each pre-funded warrant. Madrigal also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions. All of the shares in the proposed offering are to be sold by Madrigal.
Madrigal Pharmaceuticals Announces Proposed Public Offering
CONSHOHOCKEN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that it has commenced an underwritten public offering of $500 million in shares of its common stock and pre-funded warrants to purchase common stock. The purchase price of each pre-funded warrant will equal the price per share at which shares of common stock are being sold to the public in this offering, minus $0.0001, which will be the per share exercise price of each pre-funded warrant. Madrigal also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions. All of the shares in the proposed offering are to be sold by Madrigal.
03/18 10:15 EST - seekingalpha.com
Madrigal: Accelerated Rezdiffra Approval Puts It In The NASH Lead
On March 14, Madrigal Pharmaceuticals, Inc. announced that the FDA has granted accelerated approval for Rezdiffra, for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis. This accelerated approval makes Rezdiffra the first and only FDA-approved NASH treatment, which will become available in April 2024 in the US. I discuss Madrigal Pharmaceutical as an investment opportunity in this article.
Madrigal: Accelerated Rezdiffra Approval Puts It In The NASH Lead
On March 14, Madrigal Pharmaceuticals, Inc. announced that the FDA has granted accelerated approval for Rezdiffra, for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis. This accelerated approval makes Rezdiffra the first and only FDA-approved NASH treatment, which will become available in April 2024 in the US. I discuss Madrigal Pharmaceutical as an investment opportunity in this article.